Melanotan

What it is

"Melanotan" is the informal name for two synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH): Melanotan I (MT-I) and Melanotan II (MT-II). Both were developed at the University of Arizona in the 1980s and 1990s as part of a research program examining superpotent melanotropic peptides. The goal was to create a compound that could stimulate skin tanning without requiring UV radiation exposure.[3]

MT-I is a linear 13-amino-acid peptide that closely resembles natural alpha-MSH. MT-II is a shorter cyclic heptapeptide that is significantly more potent and metabolically stable than MT-I. Both bind melanocortin receptors on melanocytes to stimulate eumelanin (dark pigment) production. MT-II is non-selective: it also activates melanocortin receptors outside the skin, which is why its effects extend beyond pigmentation into sexual function, appetite, and other systems. Melanotan compounds have circulated as unregulated research chemicals for decades, earning the nickname "Barbie drug" or "tan jab" in popular media.[3]

Two pharmaceutical drugs descended from this research have received FDA approval: afamelanotide (Scenesse, a modified MT-I analog) for erythropoietic protoporphyria in 2019, and bremelanotide (Vyleesi, derived from MT-II) for hypoactive sexual desire disorder in women, also in 2019.

What researchers study it for

• Skin pigmentation and sunless tanning The original motivation for developing melanotan. A 1991 randomized, double-blind, placebo-controlled trial in JAMA found that subcutaneous administration of a synthetic melanotropin produced significant skin darkening across all skin phototypes without UV exposure, with peak effects appearing 1 to 3 weeks after dosing.[1] This established proof of principle for the melanocortin tanning mechanism.
• Sexual function and arousal MT-II's activation of MC4R receptors in the central nervous system has been studied in connection with sexual function. A 1998 double-blind, placebo-controlled crossover trial in the Journal of Urology found that subcutaneous MT-II produced clinically apparent erections in 8 of 10 men with psychogenic erectile dysfunction, with side effects including nausea, yawning, and decreased appetite.[2] This research laid the groundwork for the development of bremelanotide (PT-141).
• Photoprotection in severe photosensitivity disorders The pharmaceutical analog afamelanotide has been studied for its ability to pre-tan skin and reduce phototoxic pain in patients who cannot tolerate sunlight. A multicenter, double-blind, placebo-controlled trial published in the New England Journal of Medicine found that afamelanotide implants significantly increased pain-free sun exposure time in patients with erythropoietic protoporphyria, a rare and debilitating photodermatosis.[6]
• Melanocytic naevi changes and skin cancer risk Dermatology researchers have documented that melanocortin receptor stimulation can cause rapid and unpredictable changes in pigmented moles (melanocytic naevi). Case reports have associated unregulated melanotan use with melanoma development, raising concern about whether MC1R stimulation may accelerate malignant transformation in susceptible individuals.[5] This is an active area of safety monitoring in dermatology practice.
• Adverse event profiles from unregulated use Because melanotan compounds are widely self-administered outside clinical settings, the toxicology and dermatology literature contains documented adverse events including sympathomimetic toxicity, rhabdomyolysis, renal dysfunction, and priapism. A 2012 case report confirmed via mass spectrometry that a single overdose produced severe rhabdomyolysis (peak creatine phosphokinase 17,773 IU/L) and acute renal dysfunction requiring ICU admission.[4]

Research context

Melanotan has an unusually well-documented early human research history compared to most research peptides. The foundational 1991 JAMA trial by Levine et al. was a proper randomized controlled trial, not an animal study, and the 1998 Wessells et al. crossover study was a controlled human trial for the sexual function signal.[1][2] The pharmaceutical development that followed, resulting in two FDA approvals in 2019, validates the basic melanocortin mechanism in humans. For the EPP indication, the 2015 NEJM trial by Langendonk et al. was a multicenter RCT that directly informed regulatory approval.[6]

The situation for unregulated melanotan products sold online as research chemicals is substantially different from the regulated pharmaceutical compounds. A 2010 review by Langan, Nie, and Rhodes in the British Journal of Dermatology surveyed the public health risks of self-injected melanotan products, including uncontrolled dosing, needle-sharing risks, and unpredictable effects on pigmented skin lesions.[3] The safety profile of unregulated MT-II in particular is complicated by its non-selective receptor activation. Case reports in the clinical literature document melanoma in a melanotan user, severe rhabdomyolysis from overdose, renal infarction, and priapism, none of which were rare enough to be dismissed as isolated events.[4][5] Clinicians should be aware that patients may not volunteer melanotan use, and unexplained tanning or naevus changes should prompt inquiry.

Researchers using melanotan compounds in controlled settings use them primarily as pharmacological tool compounds to study melanocortin receptor biology, not as therapeutic candidates. The goal is understanding which receptor subtype mediates which effect, toward designing selective, single-target drugs with fewer off-target effects than MT-II.

Typical research parameters

Related research notes